Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M57.1Revenue $M0.2Net Margin (%)-9,306.0Z-Score-4.3
Enterprise Value $M35.8EPS $-0.1Operating Margin %-9,819.6F-Score5
P/E(ttm))0Cash Flow Per Share $-0.1Pre-tax Margin (%)-9,306.0Higher ROA y-yN
Price/Book1.910-y EBITDA Growth Rate %0Quick Ratio4.9Cash flow > EarningsY
Price/Sales2855-y EBITDA Growth Rate %-3.9Current Ratio4.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-45.2Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-53.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M190ROI % (ttm)-49.0Gross Margin Increase y-yY

Gurus Latest Trades with HEB

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HEBArnold Schneider 2007-03-31 Sold Out $1.65 - $2.31
($2)
$ 0.3-85%Sold Out0
HEBArnold Schneider 2006-12-31 Buy $1.96 - $2.34
($2.1)
$ 0.3-86%New holding, 10000 sh.10,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HEB is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


HEB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STRAYER DAVID RMedical Director 2012-05-18Buy50,000$0.2623.08 view
Lander Russel JVP of Process/QualityAssurance 2011-03-01Buy50,000$0.46-30.43 view
Lander Russel JVP of Process/QualityAssurance 2010-08-23Buy4,910$0.51-37.25 view
CARTER WILLIAM ACEO, 10% Owner 2010-08-10Sell377,388$0.49-34.69 view
STRAYER DAVID RMedical Director 2010-06-23Sell50,900$0.55-41.82 view
STRAYER DAVID RMedical Director 2010-06-16Buy230,586$0.57-43.86 view
Bernhardt Charles Thomas IIICFO 2010-06-15Sell87,794$0.59-45.76 view
Springate Wayne S.Vice President of Operations 2010-06-15Sell83,104$0.59-45.76 view
CARTER WILLIAM ACEO, 10% Owner 2010-06-11Buy500,000$0.66-51.52 view
Springate Wayne S.Vice President of Operations 2009-12-15Buy877$0.56-42.86 view

Press Releases about HEB :

    Quarterly/Annual Reports about HEB:

    News about HEB:

    Articles On GuruFocus.com
    Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
    Hemispherx Biopharma Inc Reports Operating Results (10-K/A) Feb 14 2011 
    Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
    Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
    Hemispherx Biopharma Inc Reports Operating Results (10-Q) Nov 08 2010 
    Weekly CEO Sells Highlight: Hemispherx Biopharma Inc, ADESA Inc, Entergy Corp, and Danaher Corp. Aug 15 2010 
    Hemispherx Biopharma Inc Reports Operating Results (10-Q) Aug 06 2010 
    Hemispherx Biopharma Inc (HEB) CEO William A Carter buys 500,000 Shares Jul 01 2010 
    Weekly CFO Buys Highlight: Wireless Telecom Group, ValueVision Media, American River Bankshares, Hem Dec 12 2009 
    Hemispherx Biopharma Inc (HEB) CFO Charles Thomas Iii Bernhardt buys 2,000 Shares Dec 08 2009 

    More From Other Websites
    Hemispherx Announces Strategic Relationship with Squire Patton Boggs, Washington, DC as Governmental... Oct 20 2014
    Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC as Governmental... Oct 20 2014
    Hemispherx Biopharma Prevails in Multi-Million Dollar Federal Lawsuit … All Claims by Cato Capital... Oct 20 2014
    8:37 am Hemispherx Biopharma prevails in multi-million dollar federal lawsuit Oct 20 2014
    Hemispherx Biopharma Prevails in Multi-Million Dollar Federal Lawsuit Oct 20 2014
    US STOCKS-Futures little changed after selloff; Ebola stocks jump Oct 13 2014
    US STOCKS-Futures little changed after selloff; Ebola stocks jump Oct 13 2014
    Hemispherx Biopharma Director Dr. William Mitchell to Present Research on Treating Deadly Emerging... Oct 07 2014
    Ebola Sector Shake Out Leaves Chimerix Inc On Top Oct 06 2014
    New month and we are off to a very rocky start... Oct 01 2014
    Tekmira: This Could Take a While Oct 01 2014
    Hemispherx Biopharma Expands Research on Potential Ebola Treatments to Five Independent... Sep 29 2014
    Hemispherx Announces Primate Research Showing Alferon(R) LDO Protection From Pulmonary Damage... Sep 22 2014
    Hemispherx' Drug Ampligen Plus Intranasal Seasonal Influenza Vaccine Induces Cross-Reactive Antibody... Sep 15 2014
    Hemispherx Biopharma and the Swiss Department of Defense, Civil Protection and Sports Expand Their... Sep 10 2014
    Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases... Sep 08 2014
    Hemispherx Biopharma to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in... Sep 03 2014
    HEMISPHERX BIOPHARMA INC Financials Aug 19 2014
    Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2014 Aug 11 2014
    HEMISPHERX BIOPHARMA INC Files SEC form 10-Q, Quarterly Report Aug 08 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK